Data & Decision Intelligence

Electrification is scaling manufacturing fast, but operational excellence still needs a rethink.

The quality engineer spent about 40 seconds at our monitoring screen before he asked his question. He didn't ask about our defect rate. He asked: "What's your process capability on this dimension across all three shifts?"

I knew the average. I didn't know the split by shift.

Over decades of manufacturing, I've sat through more customer audits than I can count at Bosch, Gabriel India, Auto Ignition, and now Endurance. Nobody had ever asked me that. That question was the first clear signal that electrification wasn't just changing the components we make. It was changing the standard by which our manufacturing is judged.

This made me realize that bigger changes were underway in how we are measured. That realization set the stage for everything that followed.

How Electrification Is Changing The Shop Floor Reality

Electrification has changed what good manufacturing means. Electric and hybrid parts need to be made with more accuracy and consistency than most traditional car parts. At Endurance, where we make brakes and suspension for companies building electric vehicles, we've had to rethink what "ready for production" means. There is less room for error, and we must be able to track every part.

The technology response was predictable and, generally speaking, correct. In-line quality monitoring, real-time process dashboards, and predictive maintenance have moved from pilot projects to core capabilities. Manufacturing systems are becoming more digitally connected, sensors and machine data allowing faster detection of variation, shifting teams from reactive problem-solving to preventive and predictive control. Plants are being redesigned with more flexible layouts, a higher automation density, and built-in traceability.

I didn't expect that being good for the environment would become so important for how well we run. Watching our energy use, using materials wisely, and making less waste are now key to staying competitive. These things are not just for CSR reports; they are part of how we work in every electric vehicle project.

The scale of this shift is visible across global manufacturing. From hubs in India to plants in Eastern Europe and Latin America, electric mobility programs are compressing development cycles, increasing quality expectations, and demanding higher levels of process stability than most operations built for ICE were designed to deliver. But as fast as these changes are happening worldwide, not every challenge is being openly discussed.

The Gap That Nobody Wants To Talk About

Even though we use more machines and digital tools, results are often not steady. I've seen this in my company and others. The problem is not what people can do, but how well they follow good routines. If the way we work is not strong, technology only shows us the problems but doesn't solve them.

There is also a skills gap. Making electric vehicles means learning new materials, safety rules, and quality standards that weren't needed before. Workers and engineers need to know both how things are made and how to use digital tools. This mix of skills is rare and takes real effort to build.

We had real-time alerts. We had dashboards. What we didn't have was a standardized response at the supervisor level across all three shifts. Problem-solving was personality-dependent; it worked when the right person was on the floor, but not when they weren't. The data was telling us everything. The team wasn't consistently acting on it.

What Actually Scales

The next phase of manufacturing excellence will be driven by integrated operating systems, shared performance frameworks, and standardized ways of working across plants and geographies, because inconsistency at scale is expensive, and electrification makes the cost visible faster than any previous transition.

People's skills will set companies apart. Being excellent comes from people working well together, helped by technology, not the other way around. The best companies will understand this and invest in their people.

Plants must be built to handle problems and bounce back. New technology helps us move faster, but true success comes from putting technology, strong work habits, and people development together, in that order.

The Question Worth Sitting With

If you're leading a manufacturing operation through this transition, the question of technology investment is probably already settled. The harder question is whether your operating model can absorb those investments and turn them into consistent output.

Your sensors will tell you everything. The important thing is what your team does with that information.

What does your plant look like at 2 AM when something goes out of control, and the right engineer isn't there? If you're not certain of the answer, that's where the real work starts.

​

Cough measurement enters its data era

Cough is one of the most common symptoms of respiratory diseases, and the number one reason why people seek medical help worldwide. Whether it's due to chronic cough, acute infections, or pre-existing conditions such as asthma and COPD, accurately understanding and measuring cough is important for exact diagnosis and treatment.

However, cough remains one of the least understood symptoms in respiratory medicine. Until recently, clinicians relied on subjective patient reports to assess cough frequency and severity, lacking objective tools for cough monitoring. This subjective aspect affects the management of diseases such as chronic cough, asthma, bronchitis, and other respiratory conditions, where a definite cough measurement is important for successful treatment.

In other words, we’ve been trying to manage coughs without a reliable measuring tool. Imagine managing a fever without a thermometer, or blood pressure without a BP monitor. Until very recently, no instrument or tool existed that could support clinical decisions with quantitative evidence. As a result, cough assessment is still stuck while almost every other domain of medicine has modernized. Innovation in cough therapeutics has basically been nonexistent.

The last time a modern regulator approved a cough drug was way back in 1958, when the FDA approved Dextromethorphan. To this day, this is the most commonly prescribed antitussive. In the last 13 years alone, more than 15 modern molecules have been abandoned or rejected by regulators because the available data failed to show a definite, objective impact and developers had no trustworthy way to prove it. The medical device sector understands this intuitively. Continuous cough monitoring, enabled by AI and digital biomarkers, is now solving this challenge and changing how clinicians approach cough assessment.

A Technological Shift

The last decade has brought two technological shifts that have changed the trajectory of cough science, digital health, and respiratory disease management.
First, AI matured. Specifically, machine learning models became capable of distinguishing nuanced acoustic patterns with high precision. Sounds could now be parsed, classified, and analyzed at scale by machines capable of “learning”.
Second, billions of people began carrying powerful sensors and processors in their pockets. Smartphones and wearables turned into ubiquitous health data collectors. Always on, always near the body.

This convergence created the missing pathway to measure cough continuously in the real world. It enabled us to develop tools that detect cough events with high accuracy, without involving specialized hardware or much infrastructure.

Using on-device acoustic AI, the models we built identify coughs securely and unobtrusively, in any environment, with minimal user effort.
More importantly, they do so over long periods, producing the kind of longitudinal data that clinical science has been missing. This is critical for coughs, which happen over time and therefore cannot be “measured” in a laboratory.

This capability is now becoming standard in respiratory research and clinical trials. Continuous cough monitoring and digital biomarkers are changing study design, endpoint definition, and the quantification of treatment impact. This innovation enables pharmaceutical companies and health service providers to access precise, reliable endpoints for respiratory disease research. In less than 5 years, Hyfe’s technology has been used in over 50 clinical studies, resulting in more than 20 peer-reviewed publications and progressing the discipline of objective cough measurement.

For startups, this illustrates a wider trend: once measurement enters a previously unmeasurable domain, the entire innovation ecosystem shifts. These dynamics mirror what has been observed in other bio signal measurements, such as glucose monitoring, cardiac rhythm analysis, and sleep science. Once accurate, passive, and scalable measurement becomes possible, an entire wave in healthcare transformation follows. The adoption of AI-powered digital biomarkers in these domains has revolutionized disease management and patient care.

The Real Challenges Are Not Technical

While the technology is advancing quickly, the barriers to adoption are rarely algorithmic. They come from institutions, incentives, and habits.

In the case of cough monitoring:
Clinicians must shift from qualitative impressions to measurable indicators. This requires new workflows, new training, and new comfort with digital biomarkers. It also adds friction (and time spent/ patient), which they can perceive as ineffective. Additionally, clinicians have a healthy distrust of “technology gimmicks, which raises the bar in proving evidence and impact.
Payers must recognize the value of measurement-rich care. Reimbursement models lag behind the clinical realities of modern respiratory disease. They also require new systems that make sense of continuous data and predictive analytics.
Regulators must treat digital tools as precision instruments. This means validating them with the same rigor as other medical devices and integrating them into guidelines and frameworks.

These impediments are significant and can be expensive, but they follow a familiar pattern seen with digital health tools such as ECGs, continuous glucose monitors, and wearable-based arrhythmia detection. Once clinical evidence accumulates and early adopters demonstrate utility, healthcare systems adjust rapidly. The digital transformation in respiratory health is following this same trajectory.

What Comes Next

Symptomomics and multi-modal respiratory monitoring: Cough frequency is one data point. Measuring it uncovers things like bursts, nocturnal/temporary patterns, etc., all of which carry a previously unknown medical signal. Modern models are amalgamating these signals into unified respiratory phenotypes, enabling the profiling of disease dynamics that were previously impossible.

Predictive models for exacerbations and disease progression: Longitudinal cough data already show patterns that precede clinical deterioration in COPD, asthma, infections, and chronic cough disorders. Expect predictive analytics to become central to case management and remote monitoring programs. It is realistic to foresee early detection of things like lung cancer based on subtle changes to cough patterns, years before symptoms are present.

Consumer wellness and therapeutics: As regulators formalize pathways for digital biomarkers, consumer-facing cough monitoring apps and wearables will expand. These tools will support behavioral therapies, early detection of respiratory diseases, environmental exposure assessment, and personalized health guidance, emulating the evolution of digital sleep and fitness technologies.

Personalized digital therapeutics: Continuous symptom surveillance enables continuous feedback loops for specific interventions. This allows for very easy personalization of factors such as dosage, timing of intervention, and environmental conditions (humidity, temperature, allergens, etc.) during therapy. This means higher impact at lower costs.

Drug development is being redesigned around continuous digital endpoints: Instead of relying on short, clinic-based assessments, clinical trials are shifting toward real-world, time-resolved metrics enabled by digital biomarkers and AI-powered cough measurement. This unlocks smaller, faster studies with more precise signals. Precision cough data is becoming a default requirement in respiratory drug evaluation and regulatory submissions.

Public Health: Aggregate, privacy-preserving cough data at the population level can support early detection of infectious disease outbreaks, track seasonal trends, and monitor environmental health impacts. This represents a new category of acoustic epidemiology with significant public health, research, and commercial applications in respiratory health analytics.

Opportunities For Builders And Innovators

The lesson from other domains is consistent: precision measurement converts stagnant fields into fertile ones. It brings structure to previously ambiguous problems. It reduces R&D failure rates. It reshapes reimbursement. It reveals entirely new categories of unmet need.
Cough monitoring is at this inflection point now.
The next generation of medical device companies in respiratory care will be built on continuous, objective data. They will create tools, therapies, and models of care that were impossible when cough was just a story patients told. Innovators who understand the historical barrier will see the scale of the opportunity once it is removed.

Why I stopped building them to save decision velocity

Dashboards often create "Insight Paralysis" slowing down business decisions. Discover why shifting from data volume to Decision Intelligence increases business value, improves decision velocity, and supports data-driven leadership.

I remember the very moment I realized I was building the wrong thing. It was a Monday morning quarterly business review with one of the large manufacturing clients in their office. I was sitting there, nursing a warm coffee, watching two VPs argue. On the screen, there were three different dashboards. Sales showed revenue was up. Marketing showed leads were down. Finance was just shaking their head because the margins didn’t match either of them.

I had invested months building those data pipelines. I thought, "If I just give them the numbers, they’ll know what to do." Instead, I watched them freeze. They weren't making decisions faster. They were just arguing about the metrics with better graphics. That was when I realized the hard truth: I had built a Ferrari engine of data, but we were stuck in traffic because we forgot how to actually drive the decision-making process.

The Shift: From Scarcity To "Insight Paralysis"

The biggest shift I’ve observed in our industry isn't AI - it’s the shift from scarcity to abundance. Five years ago, I remember begging IT teams for a report. The constraint was volume. Today, the constraint is attention.

I’ve watched organizations democratize data to the point that we’ve accidentally created a Tower of Babel. The industry data backs this up: studies show that employees now spend up to 10 hours a week just searching for the right data. Yet, shockingly, 76% admit they still make decisions without it because the insights remain too hard to access. I see this constantly: a CEO asks, "Is this product profitable?" and gets three different answers depending on who ran the SQL query. This isn’t "data-driven." This is Insight Paralysis.

I used to measure my team’s success by how many dashboards we shipped. Now, I look back at some of those "Executive Command Centers" - beautiful, complex, and totally unused - and I realize we were measuring activity, not value.

The Context Gap

Don't get me wrong - I love technology. Modern platforms can ingest millions of rows in seconds. But here is the messy truth I’ve learned: Tech has zero context.

I saw this recently with a retail client. Their dashboard showed "Inventory Turnover" was healthy (Green Light). But the dashboard didn't know that the "healthy" number was driven by low-margin clearance items, while their best sellers were out of stock. The numbers were right; the business reality was wrong. Observed a similar thing with a manufacturing client. A dashboard reported 98% machine uptime. It looked great. But the 2% downtime happened exactly during the peak rush, costing millions.

The tech gives us the signal, but it can’t filter the noise. When we expect the tool to do the thinking for us, we miss the story behind the numbers.

So, Where Do We Go From Here?

If you’re a business leader focused on analytics in 2026, it’s time to recognize that the era of the "General Purpose Dashboard" is ending. Industry experts forecast that by 2028, over 60% of dashboards will be replaced by AI-powered data storytelling, automated insights, and actionable data visualization. Leading the way requires adopting new approaches to data-driven decision-making.

I am now advising my clients to pivot toward Decision Intelligence. Instead of building generic dashboards that show everything (just in case), we need to build interfaces that recommend one action. Visualize a system that doesn't just show you "Inventory Levels." Instead, it says: "Stock is low in the East Coast warehouse. If you don't reorder by Tuesday, you will miss $50k in revenue. Click here to approve the PO."

That’s the difference. That’s moving from "Data" to "Decisions." But until technology improves there, you have a job to do. Next time you’re in that Monday meeting, and someone puts up a slide with fifty numbers on it, don't ask for more detail. Ask them this: "Which of these charts actually helped me make a decision last week?" If the answer is "none," delete it. And go enjoy your coffee.